Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miraculin for Taste Dysfunction in Head and Neck Cancer Patients Receiving Radiation Therapy
NCT05273307Phase 3Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Mar 2022
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Taste Disorders (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Taste Assessment scores at 6 months. Started Mar 2022; status: active, not recruiting.
02
Conditions
Taste Disorders
Beyond the preview
Go deeper on NCT05273307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273307.